Andrx Expects “Near Term” FDA Response To Petition Blocking Concerta Generics

McNeil’s citizen petition requests FDA apply additional bioequivalence requirements for Concerta ANDAs. With no patent exclusivity remaining on the innovator product, multiple generics could be approved if FDA rejects McNeil’s arguments.